<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250929067410N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-08</date_registration>
      <primary_sponsor>Dr. Masih Daneshvari Educational, Research and Treatment Center</primary_sponsor>
      <public_title>comparison of analgesic effect of erector spinae plane block versus intercostal nerve blck in VATS surgery under general anesthesia without opioid</public_title>
      <acronym>EVAT(erctor vs intercostal block in VATS analgesia trial)</acronym>
      <scientific_title>comparison of analgesic effect of erector spinae plane block versus intercostal nerve blck in VATS surgery under general anesthesia without opioid</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-12-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87705</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This study is a randomized clinical trial with parallel groups. After obtaining informed consent, eligible patients will be randomly assigned to two groups: Group A, receiving the erector spinae plate block, and Group B, receiving the intercostal block. The randomization method is based on four-blocks with an allocation ratio of 1:1. Pain intensity is assessed at intervals of 2, 6, 12, and 24 hours after surgery using the VAS scale. Patients and pain assessors are unaware of the assigned group. (Double-blind) Data will be analyzed using appropriate statistical tests including independent t-test and repeated analysis of variance, Randomization description: Each patient, after entering and confirming the inclusion criteria, is placed in one of two study groups: Group A: Erector Spina Plate Block (ESPB) Group B: Intercostal Block (ICB) The anesthesiologist is aware of the group assignment before the block is performed, but the patient and the pain assessor are unaware of the treatment group. This method prevents BIAS in the assessment (pain severity). If an eligible patient withdraws after allocation or the procedure is canceled, a replacement sample will be selected from the next random numerical block to keep the number of samples in the two groups equal, Blinding description: In this study, double-blinding is used. The patient and the pain assessor are unaware of the type of block. Only the anesthesiologist performing the block is aware of the type of intervention. The patient is under general anesthesia and remains unaware of the intervention. The pain assessor who measures the VAS score after surgery and the data analyst are not aware of the patients' treatment group. After collecting the data, they are entered into the statistical software with A-B codes and decoding is performed after the analysis is complete. This design prevents observer and patient bias in assessing the outcomes after pain and medication use.</study_design>
      <phase>4</phase>
      <hc_freetext>Patients who are candidates for video-assisted thoracoscopic surgery under general anesthesia without narcotics. This procedure is usually performed in patients with various lung diseases such as lung masses, pleural effusions, or lung biopsies.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: Group A: Erector spinae plate block in the lateral position after general anesthesia without narcotics and prep and drape, performed with ultrasound guidance, 20 cc of 0.25% marcaine solution is injected at the T5 level in the space between the fascia and the erector spinae muscle. The intervention is performed by an experienced anesthesiologist in this field. Number of times: once for each patient. Intervention 2: Intervention group: Intervention group: Intercostal block group, in which after general anesthesia, after positioning and before the start of surgery, 5 cc of 0.25% marcaine solution will be injected into each of the three intercostal spaces at the surgical incision site under ultrasound guidance. The total injection will be 15 cc. The intervention will be performed by an experienced anesthesiologist. The number of times is once for each patient.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data from this study, including results on pain intensity, analgesic use, and possible complications of the regional block, will be provided to the research team confidentially after the final analysis is completed. The data will be coded and only the mean and standard deviation will be published in the final report

When:
The data will be available after the final article is completed and published. This period is estimated to be approximately 6 to 12 months after the end of data collection

To whom:
The data will only be available to the project implementation group, and limited and confidential access will be provided to other researchers upon written request and approval by the ethics committee

Conditions:
The data includes pain intensity, opioid consumption, and potential side effects of the regional block technique. The data will be coded after analysis and will be used for research and educational purposes only

Where to obtain:
The request will be given to the principal investigator, and coordination and authorization will be done with the supervisor and the medical ethics committee

How to obtain:
Applicants must submit their request in writing to the principal investigator, and after approval by the supervisor and the ethics committee, it will be submitted in an encrypted format and in accordance with the principle of confidentiality

Comments:
No identifying information will be included in the shareable files, and the documents will be stored on the Masih Daneshvari research server. Only the data will appear in the final article as results</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Lida Fadaizadeh / Tahera Parsa</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran Khayaban Shahid Bahanar (Niavaran) - Darabad - Bimaristan Ray Masih Danshuri</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956944413</zip>
        <telephone>0098021027123000</telephone>
        <email>lfadaizadeh@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>lida fadaizadeh/tahereh parsa</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran Khayaban Shahid Bahanar (Niavaran) - Darabad - Bimaristan Ray Masih Danshuri</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956944413</zip>
        <telephone>+98 21 2712 3000</telephone>
        <email>lfadaizadeh@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1-   age between 18 and 70 years 2- scheduled for video - assisted thoracoscopic surgery under general anesthesia with out opioid administration.3- asa physical status 1-3  4- ability to provide witten informed consent 5- no known allergy to syudy drug (local anesthesia such as bupivacaine or ropivacaine)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1- Unwillingness to participate in the study or withdrawal at any stage 2- History of major thoracic surgery or anatomical changes that prevent proper block implementation 3- Infection at the block injection site 4- Severe cardiac, pulmonary, or renal disease that increases the risk of anesthesia 5- Coagulation disorders or use of active anticoagulant drugs 6- Pregnancy or breastfeeding 7- Inability to assess pain</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>j90 c34.9 </hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lung mass, pleural effusion, or lung biopsy condidates undergoing vats surgery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: Group A: Erector spinae plate block in the lateral position after general anesthesia without narcotics and prep and drape, performed with ultrasound guidance, 20 cc of 0.25% marcaine solution is injected at the T5 level in the space between the fascia and the erector spinae muscle. The intervention is performed by an experienced anesthesiologist in this field. Number of times: once for each patient</i_keyword>
      <i_keyword>Intervention group: Intervention group: Intercostal block group, in which after general anesthesia, after positioning and before the start of surgery, 5 cc of 0.25% marcaine solution will be injected into each of the three intercostal spaces at the surgical incision site under ultrasound guidance. The total injection will be 15 cc. The intervention will be performed by an experienced anesthesiologist. The number of times is once for each patient</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative pain intensity at 2, 6, 12, and 24 hours after surgery based on the visual analog scale (VAS). Timepoint: At 2, 6, 12, 24 hours after surgery. Method of measurement: Using a visual analogue scale (VAS) of pain by a pain assessor who is unaware of the patient grouping.</prim_outcome>
      <prim_outcome>Changes in vital signs (blood pressure, heart rate, oxygen saturation) in the hours after surgery. Timepoint: Measurement by pain assessor at 2, 6, 12, and 24 hours after surgery. Method of measurement: % -mmhg-bpm.</prim_outcome>
      <prim_outcome>Possible complications with the block, such as hematoma, pneumothorax, and hypotension. Timepoint: Clinical assessment and recording during the 24 hours after surgery. Method of measurement: Incidence percentage.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Amount of pain medication used within 24 hours after surgery. Timepoint: Record the total amount of painkillers prescribed, such as diclofenac, acetaminophen, or other narcotics, in the patient's record within 24 hours after surgery. Method of measurement: Units based on milligrams, for example 2 mg of morphine intravenously three hours after surgery.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dr. Masih Daneshvari Educational, Research and Treatment Center</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-10-12</approval_date>
        <contact_name>Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Tehran, Shahid Bahonar Street (Niavaran), Darabad Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
